Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
NLS Pharmaceutics Ltd. - Common Shares
(NQ:
NLSP
)
2.260
-0.040 (-1.74%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NLS Pharmaceutics Ltd. - Common Shares
< Previous
1
2
3
4
5
6
7
8
Next >
45 Biggest Movers From Yesterday
January 05, 2022
Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55. Hoth Therapeutics, Inc. (NASDAQ: HOTH) surged 85.7% to settle at $1.30 after the company announced...
Via
Benzinga
NLS Pharmaceutics Announces Patent Issuance in the United States for its Mazindol Extended-Release Formulation
January 04, 2022
- Key patent now granted in major markets including the U.S., Europe, Canada & South Korea - Patent claims cover use of the Company's lead product candidate, Quilience® (mazindol ER) in both attention...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
18 Stocks Moving in Monday's Pre-Market Session
January 03, 2022
Gainers Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) rose 41.6% to $3.13 in pre-market trading after gaining around 8% on Friday. Armstrong Flooring, Inc. (NYSE: AFI...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
December 06, 2021
Welcome back, trader! We're starting off another busy week with a look at the biggest pre-market stock movers for Monday!
Via
InvestorPlace
40 Stocks Moving In Thursday's Mid-Day Session
December 02, 2021
Gainers Biofrontera Inc. (NASDAQ: BFRI) surged 39% to $6.02. Biofrontera announced Notice of Allowance for U.S. patent titled 'Illumination for Photodynamic Therapy.'...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
61 Biggest Movers From Yesterday
December 03, 2021
Gainers Jowell Global Ltd. (NASDAQ: JWEL) jumped 25.5% to close at $13.36. Jowell Global recently announced a collaboration with Unilever's Uni-Excubator. Information...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
December 02, 2021
Good morning, trader! We're gearing up for another busy day of trading with the biggest pre-market stock movers for Thursday!
Via
InvestorPlace
27 Stocks Moving in Thursday's Pre-Market Session
December 02, 2021
Gainers Phunware, Inc. (NASDAQ: PHUN) rose 25.8% to $4.09 in pre-market trading after surging around 12% on Wednesday. Digital World Acquisition Corp. (NASDAQ: DWAC)...
Via
Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
December 01, 2021
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) climbed 91.7% to $6.14 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down Moderna's...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
December 01, 2021
Good morning, traders! We're starting off the day right with a look at the biggest pre-market stock movers for Wednesday!
Via
InvestorPlace
23 Stocks Moving in Wednesday's Pre-Market Session
December 01, 2021
Gainers Skylight Health Group Inc. (NASDAQ: SLHG) rose 55.3% to $2.05 in pre-market trading after dipping around 10% on Tuesday. Skylight Health Group, last month, posted a...
Via
Benzinga
NLS Pharmaceutics Announces Preclinical Results Confirming the Potential Benefit and Safety Profile of NLS-4 for Circadian Rhythm Dysregulation and Chronic Fatigue Syndrome in Long-Covid Model
November 30, 2021
STANS, SWITZERLAND / ACCESSWIRE / November 30, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
NLS Pharmaceutics CEO Issues Letter to Shareholders
November 01, 2021
STANS, SWITZERLAND / ACCESSWIRE / November 1, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Initial Public Offering
Intellectual Property
Regulatory Compliance
Exposures
Intellectual Property
Legal
Regulatory
Leading the Charge to Develop the First Orexin-Targeted Therapy to Address Narcolepsy at its Root Cause
October 20, 2021
Photo by MART PRODUCTION from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
NLS Pharmaceutics Announces Preclinical Data Demonstrating the Potential of NLS-4 (Lauflumide) to Treat Chronic Fatigue Associated With Long-COVID
October 14, 2021
STANS, SWITZERLAND / ACCESSWIRE / October 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Product Recall
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
36 of the Best Ideas Companies to Present at the Fall Harvest - Best Ideas from the Buy-Side Virtual Investor Conference on October 5th - 8th, 2021
October 04, 2021
RALEIGH, NC / ACCESSWIRE / October 4, 2021 / The Fall Harvest - Best Ideas from the Buy-Side will take place on October 5th - 8th, 2021, where 36 SmallCap, MicroCap and NanoCap public companies will be...
From
MicroCap Rodeo
Via
AccessWire
NLS Pharmaceutics to Participate in The Micro Cap Rodeo Fall Harvest Conference: Best Ideas from the Buy-side
September 30, 2021
STANS, SWITZERLAND / ACCESSWIRE / September 30, 2021 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment
September 28, 2021
STANS, SWITZERLAND / ACCESSWIRE / September 28, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
Intellectual Property
Legal
Regulatory
NLS Pharmaceutics to Participate in the Benzinga Healthcare Small Cap Conference
September 24, 2021
STANS, SWITZERLAND / ACCESSWIRE / September 24, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Initiates Phase 2 Trial for Quilience in Narcolepsy and Announces First Patient Enrolled
September 14, 2021
STANS, SWITZERLAND / ACCESSWIRE / September 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
Intellectual Property
Legal
Regulatory
NLS Pharmaceutics to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference
September 08, 2021
STANS, SWITZERLAND / ACCESSWIRE / September 8, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery...
From
NLS Pharmaceutics AG
Via
AccessWire
58 Biggest Movers From Friday
August 23, 2021
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares climbed 204.1% to close at $19.16 on Friday. Regencell Bioscience reported partial exercise of underwriter...
Via
Benzinga
38 Stocks Moving In Friday's Mid-Day Session
August 20, 2021
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares climbed 45.8% to $6.27 after the company presented data from ongoing studies of its preventive vaccine against COVID-19, showing...
Via
Benzinga
Exposures
COVID-19
22 Stocks Moving in Friday's Pre-Market Session
August 20, 2021
Gainers GeoVax Labs, Inc.. (NASDAQ: GOVX) shares rose 72.1% to $7.40 in pre-market trading after the company announced it presented COVID-19 vaccine data at the European Society...
Via
Benzinga
Exposures
COVID-19
NLS Pharma Stock Gains After Issuance Of Mazindol Patent
August 19, 2021
NLS Pharmaceutics Ltd (NASDAQ: NLSP) has received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application No. 16/083,131. ...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Application Covering its Proprietary Mazindol Formulation
August 19, 2021
STANS, SWITZERLAND / ACCESSWIRE / August 19, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
Intellectual Property
Legal
Product Safety
NLS Pharmaceutics to Participate in the Canaccord Genuity 41st Annual Growth Conference
August 05, 2021
STANS, SWITZERLAND / ACCESSWIRE / August 5, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Announces the Appointment of Eric Konofal, M.D., Ph.D. as Chief Scientific Officer
July 19, 2021
STANS, SWITZERLAND / ACCESSWIRE / July 19, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
NLS Pharma Stock Gains As Its Narcolepsy Candidate To Enter Mid-Stage Study Next Month
July 15, 2021
The FDA has accepted NLS Pharmaceutics Ltd's (NASDAQ: NLSP) Investigational New Drug application for Quilience (mazindol extended-release (mazindol ER), the...
Via
Benzinga
Exposures
Product Safety
NLS Pharmaceutics Announces FDA Acceptance of IND Application to Initiate Clinical Trials with Quilience(R) (mazindol ER) to Treat Narcolepsy
July 15, 2021
Planned Phase 2a clinical trial anticipated to commence in August 2021 STANS, SWITZERLAND / ACCESSWIRE / July 15, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
Intellectual Property
Legal
Product Safety
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.